Global Telepathology Service Market Overview:
The telepathology service market is expected to gain market growth in the forecast period due to the growing awareness amongst physicians and patients regarding the benefits of telepathology service. Telepathology is described as the electronic transmission of high-quality pathological data over a long distance using telecommunications technology. It paves the way for the transfer of high-resolution image-rich pathological data between locations for diagnostic, educational, and research purposes. Telepathology is a new technology that uses advances in telecommunication to access patients in remote locations and make the strongest diagnostic inference to a distance healthcare provider.
- Surging volume of patients suffering from chronic disorders
- Rising clinical urgency to accept telepathology to improve present patient diagnostic imaging events
- Advances in laboratory diagnostic tests
- High initial setup cost along with error in sampling pathological data
- Rising penetration of internet connectivity along with an advanced source of revenue for the pathologists through expanded consultative practice
- Growth in emerging countries
- Lack of skilled professionals
The global Telemedicine market is moderately competitive due to the presence of many small and large market players. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with fewer prices.
Some of the key players profiled in the report are Canada Health Infoway (Canada), University Health Network (Canada), Meyer Instruments, Inc. (United States), Telemedicine Clinic (TMC) (Spain), AMD Global Telemedicine, Inc. (United States), Nationwide Medical Licensing (United States), Polycom, Inc (United States), Remote Medical Technologies (United States), USAC - Universal Service Administrative Company (United States) and Wolf Vision Inc.(United States). Analyst at AMA Research see United States Players to retain maximum share of Global Telepathology Service market by 2026. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Telepathology Service market.
Latest Market Insights:
In July 2018 – Leica Biosystems has announced that its live view telepathology system, the Aperio LV1 IVD, can now be used for on-screen diagnosis in Europe, Canada, New Zealand, and Australia. This compact Digital Pathology system, with a capacity of 4 slides, navigates like a conventional microscope, but with a host of digital benefits.
In Aug 2020, Motic Digital Pathology this week announced the global launch of its telepathology program, which allows pathologists to connect with labs and patients around the world.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Telepathology Service market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Telepathology Service market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Telepathology Service Provider, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.